Kyle Kirkland, DO
Cornea and External Diseases Specialist · College Station, TXNPI 1013371038
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,159 of the $1,512 with a category attached, or 76.7%. 18 manufacturers reported payments, led by Alcon at 27.8% of the total. 2025 is the largest year on record at $515, 2.7 times the $191 reported in 2021.
Across 46 payments — averaging $32.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$420
- AbbVie$224
- Biotissue Holdings Inc.$186
- Rxsight Inc$116
- Sun Pharmaceutical Industries Inc.$96
- Regeneron Healthcare Solutions, Inc.$71
- plus $399 from 12 others
Across 2 payments — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$12K
What the payments were for
- Travel & lodging$35323%
- Food & beverage$1,15977%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 5 | $420 |
| AbbVie(2 entities) | 7 | $224 |
| Biotissue Holdings Inc. | 2 | $186 |
| Rxsight Inc | 5 | $116 |
| Sun Pharmaceutical Industries Inc. | 4 | $96 |
| Regeneron Healthcare Solutions, Inc. | 4 | $71 |
| Harrow Eye, LLC | 3 | $62 |
| Bausch & Lomb Americas Inc. | 3 | $55 |
| Sight Sciences, Inc. | 2 | $53 |
| Dompe US, Inc. | 2 | $52 |
| Tarsus Pharmaceuticals, Inc. | 2 | $41 |
| Amgen | 1 | $29 |
| Lensar, Inc. | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Glaukos Corporation | 1 | $19 |
| GSK | 1 | $14 |
| Oyster Point Pharma, Inc. | 1 | $13 |
| NEW World Medical,inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS MULTIDOSE$125
- Prokera$104
- AmnioGraft$104
How this compares
$1,512 in reported general payments places this provider in the 65th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 93 | $94,515 |
| ProlensaBromfenac Sodium | 269 | $94,053 |
| InveltysLoteprednol Etabonate | 170 | $48,971 |
| XiidraLifitegrast | 27 | $30,581 |
| CequaCyclosporine | 27 | $26,620 |
| VyzultaLatanoprostene Bunod | 47 | $25,103 |
| Cyclosporine | 35 | $23,656 |
| LumiganBimatoprost | 31 | $15,414 |
| MoxifloxacinMoxifloxacin Hcl | 489 | $9,729 |
| Prednisolone Acetate | 189 | $8,446 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $6,225 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,289 |
| Brimonidine Tartrate | 41 | $2,656 |
| ValacyclovirValacyclovir Hcl | 27 | $2,058 |
| Latanoprost | 119 | $1,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $224 | $116,155141 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $55 | $55,68474 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $96 | $26,62027 claims |
| AlconSimbrinza | $420 | $3,28914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in College Station
- Forrest SwannWaco$111K
- Stella KimHouston$58K
- Rachel GelmanMcAllen$54K
- Ravi PatelRound Rock$9K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Margaret HubbellTexarkana$4K
- Ardalan SharifiGalveston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.